Curaleaf Holdings, Inc. (OTCMKTS:CURLF – Free Report) – Investment analysts at Atb Cap Markets reduced their Q3 2024 earnings per share estimates for Curaleaf in a report released on Thursday, August 8th. Atb Cap Markets analyst F. Gomes now anticipates that the company will earn ($0.04) per share for the quarter, down from their prior estimate of ($0.03). The consensus estimate for Curaleaf’s current full-year earnings is ($0.21) per share. Atb Cap Markets also issued estimates for Curaleaf’s Q4 2024 earnings at ($0.03) EPS and FY2024 earnings at ($0.21) EPS.
Separately, Needham & Company LLC reissued a “buy” rating and set a $6.25 price objective on shares of Curaleaf in a report on Thursday, August 8th.
Curaleaf Stock Down 0.5 %
Shares of OTCMKTS:CURLF opened at $3.12 on Monday. Curaleaf has a 12-month low of $2.51 and a 12-month high of $6.40. The company has a current ratio of 0.72, a quick ratio of 0.36 and a debt-to-equity ratio of 0.74. The firm has a market cap of $2.02 billion, a PE ratio of -8.00 and a beta of 0.88. The company has a fifty day simple moving average of $3.97 and a 200 day simple moving average of $4.70.
Curaleaf (OTCMKTS:CURLF – Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The business had revenue of $342.29 million during the quarter, compared to analyst estimates of $344.57 million. Curaleaf had a negative net margin of 20.29% and a negative return on equity of 14.43%.
Curaleaf Company Profile
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
See Also
- Five stocks we like better than Curaleaf
- What is a buyback in stocks? A comprehensive guide for investors
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- Insider Trading – What You Need to Know
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- Stock Dividend Cuts Happen Are You Ready?
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.